Evidence map›Paper›PMID 40976985›Full record

ArticleBritish journal of haematology2025

Epigenetic dysregulation and therapeutic targeting of RET receptor tyrosine kinase in high-risk KMT2A-rearranged acute myeloid leukaemia.

Arundhati Chavan, Brendan Frett, Daniel T Armstrong, Baku Acharya, Pamela Lockyer, Marjan Boerma, Samrat Roy Choudhury

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arundhati ChavanDivision of Hematology/Oncology, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Brendan FrettDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Daniel T ArmstrongDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Baku AcharyaDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Pamela LockyerDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Marjan BoermaDepartment of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Samrat Roy ChoudhuryDivision of Hematology/Oncology, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID https://orcid.org/0000-0002-6555-3031

Funding

Translational Regulation in Normal Erythropoiesis and Diamond Blackfan AnemiaP20GM121293 · NIGMS · ARKANSAS CHILDREN'S HOSPITAL RES INST · PI Alan Tackett · 2017 to 2026
$27.6M
Congressionally Directed Medical Research Programs HT9425-24-1-0932NIGMS NIH HHS 2P20GM121293NIGMS NIH HHS P20 GM121293
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CDK8‐MED12KMT2A‐rearranged leukemiaRET‐receptor tyrosine kinase

Identifiers

PMID40976985
PMCPMC13032854

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.